New York, New York (PRWEB) September 03, 2014
Testosterone lawsuits (http://www.testosteronelawsuit2014.com) filed on behalf of men who allegedly suffered serious cardiovascular problems due to their use of AndroGel and other low testosterone therapy medications continue to move forward in U.S. District Court, Northern District of Illinois, Bernstein Liebhard LLP reports. According to a Case Management Order issued on August 25, 2014, the Court has established a discovery plan for the proceeding. Among other things, the Order directs the parties to submit initial disclosures regarding certain potential witnesses and documents within the next 45 days. The parties must also continue negotiations regarding the contents of a Plaintiff’s Fact Sheet in advance of the litigation’s September Status Conference. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
“Our Firm has heard from a number of men who were allegedly injured by AndroGel and other prescription treatments for low testosterone. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.
Testosterone Treatment Lawsuits
Court documents indicate that just over 170 testosterone treatment lawsuits are now pending in the Northern District of Illinois. All of the claims filed thus far accuse the manufacturers of AndroGel, AndroDerm, Testim and other testosterone replacement therapies of concealing the cardiovascular risks associated with their products, and of failing to warn doctors and patients about their potential to cause serious heart problems.
According to court records, testosterone lawsuit filings began to grow shortly after the U.S. Food & Drug Administration (FDA) announced that it was investigating the cardiovascular risks potentially associated with this class of drugs. The agency is scheduled to convene an outside panel of advisors on September 17th to discuss this matter, and to explore ways in which such risks might be mitigated.
Men who allegedly experienced dangerous cardiovascular events due to low testosterone therapy may be entitled to compensation for their injury-related damages. Find out more about filing a testosterone treatment lawsuit by visiting Bernstein Liebhard LLP’s website, or calling the Firm today at 800-511-5092.
*fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/testosterone-lawsuit/testosterone-heart-attack/prweb12141010.htm.
Copyright©2014 Vocus, Inc.
All rights reserved